AstraZeneca reported Phase 3 success for tozorakimab (a systemic IL-33-blocking antibody candidate) across two COPD trials, Oberon and Titania. The program met its main goal in a broader-than-expected patient population, including former and current smokers across eosinophil counts and COPD severity stages. Analysts had viewed the outcome as surprising given that other IL-33 blockers had faced setbacks or failures in late-stage testing, and AstraZeneca did not release full datasets in the announcement. The company said details will be disclosed at an upcoming medical meeting. If approved, tozorakimab could expand the biologics-eligible COPD segment beyond eosinophil-selected populations, potentially reshaping competitive dynamics in COPD immune-targeted therapies.